Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 4 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Thrombotic Thrombocytopenic Purpura Overview | 7 | 1 |
| Therapeutics Development | 8 | 2 |
| Pipeline Products for Thrombotic Thrombocytopenic Purpura Overview | 8 | 1 |
| Pipeline Products for Thrombotic Thrombocytopenic Purpura Comparative Analysis | 9 | 1 |
| Thrombotic Thrombocytopenic Purpura Therapeutics under Development by Companies | 10 | 1 |
| Thrombotic Thrombocytopenic Purpura Therapeutics under Investigation by Universities/Institutes | 11 | 1 |
| Thrombotic Thrombocytopenic Purpura Pipeline Products Glance | 12 | 3 |
| Late Stage Products | 12 | 1 |
| Clinical Stage Products | 13 | 1 |
| Early Stage Products | 14 | 1 |
| Thrombotic Thrombocytopenic Purpura Products under Development by Companies | 15 | 1 |
| Thrombotic Thrombocytopenic Purpura Products under Investigation by Universities/Institutes | 16 | 1 |
| Thrombotic Thrombocytopenic Purpura Companies Involved in Therapeutics Development | 17 | 8 |
| Ablynx NV | 17 | 1 |
| Biogen Inc | 18 | 1 |
| Glenmark Pharmaceuticals Ltd. | 19 | 1 |
| Hansa Medical AB | 20 | 1 |
| Kaketsuken K.K. | 21 | 1 |
| Lee's Pharmaceutical Holdings Limited | 22 | 1 |
| Octapharma AG | 23 | 1 |
| Omeros Corporation | 24 | 1 |
| Thrombotic Thrombocytopenic Purpura Therapeutics Assessment | 25 | 9 |
| Assessment by Monotherapy Products | 25 | 1 |
| Assessment by Target | 26 | 2 |
| Assessment by Mechanism of Action | 28 | 2 |
| Assessment by Route of Administration | 30 | 2 |
| Assessment by Molecule Type | 32 | 2 |
| Drug Profiles | 34 | 26 |
| ARC-15105 Drug Profile | 34 | 1 |
| BAX-930 Drug Profile | 35 | 2 |
| caplacizumab Drug Profile | 37 | 3 |
| GBR-600 Drug Profile | 40 | 1 |
| OMS-721 Drug Profile | 41 | 6 |
| plasma (human) Drug Profile | 47 | 1 |
| Recombinant ADAMTS-13 Replacement for Thrombotic Thrombocytopenic Purpura Drug Profile | 48 | 1 |
| Recombinant Enzyme to Inhibit Immunoglobulin G for Kidney Transplantation, Central Nervous System and Autoimmune Disorders Drug Profile | 49 | 4 |
| rituximab Drug Profile | 53 | 5 |
| ZK-001 Drug Profile | 58 | 2 |
| Thrombotic Thrombocytopenic Purpura Dormant Projects | 60 | 1 |
| Thrombotic Thrombocytopenic Purpura Product Development Milestones | 61 | 12 |
| Featured News &Press Releases | 61 | 1 |
| Oct 11, 2016: First patient treated with IdeS in Phase II study in acquired Thrombotic Thrombocytopenic Purpura | 61 | 1 |
| Sep 29, 2016: Ablynx First-In-Class Wholly-Owned Anti-vWF Nanobody, Caplacizumab, May Have The Potential To Reduce Morbidity And Mortality Associated With Acquired TTP | 61 | 1 |
| May 26, 2016: Ablynx To Present A Post-Hoc Analysis Of The Phase II Titan Study With Caplacizumab In Acquired Ttp Patients At The 21St Congress Of The European Hematology Association | 62 | 1 |
| Feb 11, 2016: New England Journal Of Medicine Publishes Ablynx Phase II Titan Study Of Caplacizumab in Patients With Acquired TTP | 63 | 1 |
| Sep 29, 2015: Ablynx Initiates A Multinational Phase III Study With Caplacizumab In Patients With Acquired TTP | 64 | 1 |
| Jun 17, 2015: Ablynx Announces Presentations On Its Potential First-In-Class Treatment For Acquired TTP, Caplacizumab, At The 2015 Annual Meeting Of The ISTH | 64 | 1 |
| Feb 19, 2015: Omeros Phase 2 OMS721 Trial Resulting in Extended Access for Compassionate Use | 65 | 1 |
| Dec 08, 2014: Additional Clinical Data From The Phase II Study With Ablynx'S Anti-Vwf Nanobody, Caplacizumab, Presented At The American Society Of Hematology Annual Meeting | 66 | 1 |
| Nov 26, 2014: Ablynx Demonstrates Bioequivalence Between Liquid And Lyophilised Formulations Of Its Anti Vwf nanobody, Caplacizumab | 67 | 1 |
| Jun 17, 2014: Ablynx's Anti-vWF Nanobody, Caplacizumab, achieves Clinical Proof-of-concept in Phase II Titan Study | 68 | 1 |
| Apr 03, 2014: Investigational New Drug Application Cleared by FDA for OMS721 in Thrombotic Microangiopathies | 69 | 1 |
| Jul 28, 2011: Initial Observations Of ABLYNX S PHASE II TTP Program Presented At ISTH Congress | 70 | 1 |
| Sep 30, 2010: Ablynx Initiates Phase II Clinical Trial For ALX-0081 | 71 | 1 |
| Sep 30, 2010: Ablynx Initiates Phase II Clinical Trial For Thrombotic Thrombocytopenic Purpura | 71 | 1 |
| Sep 30, 2010: Ablynx Initiates Phase II Clinical Trial For Thrombotic Thrombocytopenic Purpura | 72 | 1 |
| Appendix | 73 | 2 |
| Methodology | 73 | 1 |
| Coverage | 73 | 1 |
| Secondary Research | 73 | 1 |
| Primary Research | 73 | 1 |
| Expert Panel Validation | 73 | 1 |
| Contact Us | 73 | 1 |
| Disclaimer | 74 | 1 |